Saturday, July 11, 2026

Patent intelligence · US

US 12005126

Compositions for oral administration of pentosan polysulfate in form of nanoparticles with improved intestinal absorption

granted A61KA61K31/722A61K31/737A61K47/61
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 18
Applicant portfolio 308
Patent details — US 12005126
Jurisdiction
US
Status
granted
Grant date
Jun 11, 2024
Expiration
Jun 6, 2044
Applicant
ALMIRA PHARMA SRL
Claims
3
CPC classes
A61K, A61K31/722, A61K31/737, A61K47/61
View on Google Patents ↗

Quick answer

US 12005126 (Compositions for oral administration of pentosan polysulfate in form of nanoparticles with improved intestinal absorption) is held by ALMIRA PHARMA SRL. Status: granted. Granted Jun 11, 2024. Expires Jun 6, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
ALMIRA PHARMA SRL
Grant date
Expiration
Claims
3
CPC classes
A61K, A61K31/722, A61K31/737, A61K47/61, A61K47/6939, A61K47/6943

More from ALMIRA PHARMA SRL

Related pharmaceutical patents in our USPTO index.

  1. US 12421228

    Naphthyridine derivatives as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  2. US 12421253

    Tetrahydropyridopyrimidine pan-KRas inhibitors

    Mirati Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  3. US 12414911

    Topical compositions and methods of use

    MIRACLE FRUIT OIL L.L.C. · Expires Sep 11, 2045

    granted
  4. US 12412764

    Substrate-accommodating container

    MIRAIAL CO., LTD. · Expires Sep 4, 2045

    granted
  5. US 12398154

    Azaquinazoline pan-KRas inhibitors

    Mirati Therapeutics, Inc. · Expires Aug 21, 2045

    granted
  6. US 12383503

    Adagrasib solid pharmaceutical compositions

    Mirati Therapeutics, Inc. · Expires Aug 7, 2045

    granted
  7. US 12377101

    Combination therapies

    Mirati Therapeutics, Inc. · Expires Jul 31, 2045

    granted
  8. US 12371435

    Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Expires Jul 24, 2045

    granted

Frequently asked questions

What is US patent 12005126?

US 12005126 (Compositions for oral administration of pentosan polysulfate in form of nanoparticles with improved intestinal absorption) is held by ALMIRA PHARMA SRL. Status: granted. Granted Jun 11, 2024. Expires Jun 6, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12005126?

ALMIRA PHARMA SRL is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.

When does US 12005126 expire?

Our index shows an expiration date of Jun 6, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.